Hybrid compounds: from simple combinations to nanomachines (Q34125590)

31 July 2017

title

Hybrid compounds: from simple combinations to nanomachines (English)

1 reference

31 July 2017

Heinrich Sticht

2

0 references

author name string

Andreas Müller-Schiffmann

series ordinal

1

1 reference

31 July 2017

Carsten Korth

series ordinal

3

1 reference

31 July 2017

publication date

1 February 2012

1 reference

31 July 2017

1 reference

31 July 2017

volume

26

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

21-31

1 reference

Multi-target-directed ligands to combat neurodegenerative diseases

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Recent progress in the development of synthetic hybrids of natural or unnatural bioactive compounds for medicinal chemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Molecular hybridization: a useful tool in the design of new drug prototypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Selection of a trioxaquine as an antimalarial drug candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Crystal structure of botulinum neurotoxin type A and implications for toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Crystal structure of DNA-bound Co(III)·bleomycin B2: Insights on intercalation and minor groove binding

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Botulinum neurotoxin: a marvel of protein design

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Hybrid molecules with a dual mode of action: dream or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Evidence for high-valent iron-oxo species active in the DNA breaks mediated by iron-bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Combinatorial approaches to the prevention and treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Dual inhibition: a novel promising pharmacological approach for different disease conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Quinpramine is a novel compound effective in ameliorating brain autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Novel Rational Drug Design Strategies with Potential to Revolutionize Malaria Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Trioxaquines and heme-artemisinin adducts inhibit the in vitro formation of hemozoin better than chloroquine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Recent trends in targeted anticancer prodrug and conjugate design

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Combining independent drug classes into superior, synergistically acting hybrid molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

The Development of New Therapeutics for Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Mirror-image phage display: aiming at the mirror

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Aptamers and aptamer targeted delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Aptamer:toxin conjugates that specifically target prostate tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Aptamer mediated siRNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Targeting the undruggable proteome: the small molecules of my dreams

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Two-headed PROTAC: an effective new tool for targeted protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Modular nanotransporters of anticancer drugs conferring cell specificity and higher efficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Targeting cancer cells by novel engineered modular transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Preclinical and clinical studies of anticancer agent-incorporating polymer micelles

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Impact of nanotechnology on drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597630-000000000-00000

10.2165/11597630-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1046095663

0 references

1 reference